Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 05 July, 2012 and appeared in  PathologyIssue 633

Hormone Discovered That Preserves Insulin Production and Beta Cell Function in Diabetes

Duke University Medical Center researchers have found protective, anti-diabetic functions for a hormone that, like insulin, is produced by the islet cells of the pancreas.... 

Advertisement

The new hormone was found to stimulate insulin secretion from rat and human islet cells and protect islet cells in the presence of toxic, cell-killing factors used in the study.

The findings provide insight into the health and survival of beta cells, a type of islet cell that produces insulin to regulate sugar levels. The discovery could open pathways for further research toward prevention and treatments for type 1 diabetes and type 2 diabetes.

The researchers gave the hormone, TLQP-21 to Zucker Diabetic Fatty rats, which have a genetic propensity to develop type 2 diabetes. They saw a significant improvement in insulin and glucose (sugar) levels and less beta cell death in the treated animals.

Senior author Christopher B. Newgard, Ph.D., director of the Sarah W. Stedman Nutrition and Metabolism Center, stated that, "We think this finding is important because it is the first demonstration that TLQP-21 prevents deterioration of the beta cells and stimulates insulin secretion in the presence of glucose." "Because diabetes starts to take hold when the number of beta cells dwindles and insulin production drops, finding the best way to produce more of this protective hormone could be valuable."

Although the researchers have so far only tested TLQP-21 in models of type 2 diabetes, they plan to test the hormone in type 1 in future studies.

TLQP-21 is similar in some of its functions to another naturally occurring hormone produced in the digestive tract, glucagon-like peptide-1 (GLP-1). Through different mechanisms, both hormones protect and promote insulin secretion. GLP-1 or drugs that stabilize it are widely used to treat type 2 diabetes, but with some side effects, including increased heart rate and reduced stomach emptying; the effect on intestinal function has caused some people to stop the therapy.

"What's exciting is that in the animal studies of TLQP-21, we didn't see these side effects," said lead author Samuel B. Stephens, Ph.D., a postdoctoral researcher in the Stedman Center. "The rats had typical appetites and ate normal amounts of food, and didn't show any changes in heart rate or digestion patterns when they were given large doses of the hormone." The next step is to find a small molecule that could stimulate the islet cells to produce more of the TLQP-21 hormone, or to develop more potent or stable versions of injected hormone.

Cell Metabolism, July 3, 2012 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 July, 2012 and appeared in  PathologyIssue 633

Past five issues: Issue 677 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 | Diabetes Clinical Mastery Series Issue 135 | Issue 675 |

2013 Most Popular Articles:

AACE Releases New Comprehensive Diabetes Management Algorithm
Posted April 25, 2013
Discovery Raises Hope for Type 1 Diabetes Reversal
Posted May 03, 2013
AACE - New Diabetes Guidelines Based on Tailored Approach
Posted May 09, 2013
AACE: Ralph A. DeFronzo, MD -- Diabetes Prevention Supports More Aggressive and Earlier Intervention
Posted May 09, 2013
Intermittent Fasting May Improve Diabetes and Reduce Cardiovascular Risk
Posted May 03, 2013
AACE – New Test Efficiently Detects Diabetic Neuropathy
Posted May 09, 2013
AACE: CAD Risk for Pre-Diabetes Similar to Diabetes
Posted May 09, 2013
New Pill in the Works for Type 1 Patients
Posted April 19, 2013
Low-Glycemic Diet Seen to Reverse Diastolic Dysfunction of Diabetes
Posted May 03, 2013
New Updated Hypoglycemia Classifications
Posted April 19, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
What test do you use to screen for prediabetes?

Navigate Diabetes In Control



Search Articles On Diabetes In Control